CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has led to profound and durable tumor responses in a relevant subset of patients with relapsed/refractory (r/r) B-cell lymphomas. Still, some patients show insufficient benefit or relapse after CAR T-cell therapy. We performed a retrospective study to i...

Full description

Bibliographic Details
Main Authors: Valerie Wittibschlager, Ulrike Bacher, Katja Seipel, Naomi Porret, Gertrud Wiedemann, Claudia Haslebacher, Michèle Hoffmann, Michael Daskalakis, Dilara Akhoundova, Thomas Pabst
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
CAR T-cell persistence
CAR T-cell therapy
B-cell lymphoma
ddPCR
Online Access:https://www.mdpi.com/1422-0067/24/6/5688

Internet

https://www.mdpi.com/1422-0067/24/6/5688

Similar Items